Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Sell
50
NVRO Quote, Financials, Valuation and Earnings
Last price:
$5.78
Seasonality move
:
-5.06%
Day range:
$5.77 - $5.81
52-week range:
$3.17 - $14.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.52x
P/B ratio:
0.96x
Volume:
3.5M
Avg. volume:
1.7M
1-year change:
-57.9%
Market cap:
$221.8M
Revenue:
$408.5M
EPS (TTM):
-$3.05
Analysts' Opinion
-
Consensus RatingNevro has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.53, Nevro has an estimated upside of 13.03% from its current price of $5.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.70 representing 100% downside risk from its current price of $5.78.
Fair Value
-
According to the consensus of 12 analysts, Nevro has 13.03% upside to fair value with a price target of $6.53 per share.
NVRO vs. S&P 500
-
Over the past 5 trading days, Nevro has underperformed the S&P 500 by -1.51% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nevro does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nevro revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Nevro reported revenues of $105.5M.
Earnings Growth
-
Nevro has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nevro reported earnings per share of -$1.41.
Enterprise value:
154.9M
EV / Invested capital:
0.34x
Price / LTM sales:
0.52x
EV / EBIT:
--
EV / Revenue:
0.38x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-5.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$269.5M
Return On Assets:
-19%
Net Income Margin (TTM):
-27.77%
Return On Equity:
-42%
Return On Invested Capital:
-23.22%
Operating Margin:
-21.79%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $406.4M | $425.2M | $408.5M | $116.2M | $105.5M | |
| Gross Profit | $276.4M | $290.1M | $269.5M | $81.5M | $65.9M | |
| Operating Income | -$98.8M | -$99.3M | -$94.7M | -$11.8M | -$23M | |
| EBITDA | $21M | -$78.3M | -$71.3M | -$9.1M | -$43M | |
| Diluted EPS | -$0.01 | -$2.57 | -$3.05 | -$0.25 | -$1.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $753.1M | $531.2M | $562.9M | $530.9M | $476M | |
| Total Assets | $789.4M | $574.5M | $602.4M | $635.7M | $553.8M | |
| Current Liabilities | $239.2M | $82.2M | $79.2M | $83.4M | $102.9M | |
| Total Liabilities | $401M | $270.9M | $278.5M | $342.6M | $322.8M | |
| Total Equity | $388.5M | $303.6M | $323.9M | $293.1M | $231M | |
| Total Debt | $310.5M | $151.3M | $186.9M | $211.5M | $225.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $24.7M | -$58.8M | -$19.4M | -$8.9M | $18.6M | |
| Cash From Investing | $64.3M | -$7.2M | $14.6M | -$1.1M | $5.3M | |
| Cash From Financing | -$2.5M | $49.5M | -$4.2M | $48.7M | $632K | |
| Free Cash Flow | $17.1M | -$67.4M | -$29.2M | -$10.8M | $16.6M | |
NVRO
Sector
Market Cap
$221.8M
$37.4M
Price % of 52-Week High
39.32%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-57.9%
-38.36%
Beta (5-Year)
0.943
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.79
200-day SMA
Sell
Level
$6.05
Bollinger Bands (100)
Buy
Level
4.09 - 5.57
Chaikin Money Flow
Sell
Level
-2.5M
20-day SMA
Buy
Level
$5.75
Relative Strength Index (RSI14)
Buy
Level
67.93
ADX Line
Buy
Level
49.08
Williams %R
Neutral
Level
-40
50-day SMA
Buy
Level
$5.08
MACD (12, 26)
Buy
Level
0.16
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Sell
Level
-7.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.7565)
Sell
CA Score
(Annual)
Level (-1.1159)
Buy
Beneish M-Score
(Annual)
Level (-3.5748)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.3705)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
Stock Forecast FAQ
In the current month, NVRO has received 0 Buy ratings 12 Hold ratings, and 0 Sell ratings. The NVRO average analyst price target in the past 3 months is $6.53.
-
Where Will Nevro Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nevro share price will rise to $6.53 per share over the next 12 months.
-
What Do Analysts Say About Nevro?
Analysts are divided on their view about Nevro share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nevro is a Sell and believe this share price will drop from its current level to $4.70.
-
What Is Nevro's Price Target?
The price target for Nevro over the next 1-year time period is forecast to be $6.53 according to 12 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is NVRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nevro is a Hold. 12 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NVRO?
You can purchase shares of Nevro via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nevro shares.
-
What Is The Nevro Share Price Today?
Nevro was last trading at $5.78 per share. This represents the most recent stock quote for Nevro. Yesterday, Nevro closed at $5.78 per share.
-
How To Buy Nevro Stock Online?
In order to purchase Nevro stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
48
SMTC alert for Mar 18
Semtech [SMTC] is down 1.22% over the past day.
Buy
67
PLPC alert for Mar 18
Preformed Line Products [PLPC] is up 0.87% over the past day.
Buy
58
NUTX alert for Mar 18
Nutex Health [NUTX] is down 1.31% over the past day.
